Food‐effect study of nilotinib in chronic myeloid leukaemia (NiFo study): Enabling dose reduction and relief of treatment burden-Reference-Cited by-同舟云学术

Food‐effect study of nilotinib in chronic myeloid leukaemia (NiFo study): Enabling dose reduction and relief of treatment burden

Published:2020-04-16 Issue:2 Volume:105 Page:148-155
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Boons Christel C. L. M.¹²^ORCID,Hartog Yvonne M.³,Janssen Jeroen J. W. M.³,Zandvliet Anthe S.¹,Vos René M.¹,Swart Eleonora L.¹,Hendrikse N. Harry¹⁴,Hugtenburg Jacqueline G.¹²

Affiliation:

1. Amsterdam UMC Vrije Universiteit AmsterdamDepartment of Clinical Pharmacology and PharmacyCancer Centre Amsterdam Amsterdam The Netherlands

2. Amsterdam UMCVrije Universiteit AmsterdamAmsterdam Public Health Research Institute Amsterdam The Netherlands

3. Amsterdam UMC Vrije Universiteit AmsterdamDepartment of HaematologyCancer Centre Amsterdam Amsterdam The Netherlands

4. Amsterdam UMC Vrije Universiteit AmsterdamDepartment of Radiology and Nuclear MedicineCancer Centre Amsterdam Amsterdam The Netherlands

Funder

ZonMw

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.13418

Reference24 articles.

1. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2. Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring

3. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

4. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial

5. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical pharmacokinetics and drug–drug interactions of tyrosine-kinase inhibitors in chronic myeloid leukemia: A clinical perspective;Critical Reviews in Oncology/Hematology;2024-03

2. The use of microtracers in food‐effect trials: An alternative study design for toxic drugs with long half‐lives exemplified by the case for alectinib;Clinical and Translational Science;2023-10-12

3. Current and emerging tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia in young adults;Expert Opinion on Pharmacotherapy;2023-07-27

4. Enhanced biopharmaceutical performance of brick dust molecule nilotinib via stabilized amorphous nanosuspension using a facile acid–base neutralization approach;Drug Delivery and Translational Research;2023-04-06

5. Pharmacokinetic Boosting of Kinase Inhibitors;Pharmaceutics;2023-04-05